Arrowhead Pharmaceuticals Raises $45M In PIPE

Pasadena-based Arrowhead Pharmaceuticals, a biopharmaceuticals developer aiming at treating hepatitis and other diseases has raised $45M in a private offering, the company said today. The publicly held firm, which trades as ARWR on the NASDAQ, said the funding came from Orbimed, RA Capital Management, Perceptive Advisors, RTW Investments, and others. The company said the private offering was managed by Cantor Fitzgerald & Co., with Trout Capital LLC and Chardan Capital Markets LLC acting as financial advisors. More information »